Compare · ACHV vs ORKA
ACHV vs ORKA
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.63B, about 6.9x ACHV ($526.6M).
- ORKA has been more active in the news (11 items in the past 4 weeks vs 10 for ACHV).
- ORKA has more recent analyst coverage (11 ratings vs 8 for ACHV).
- Company
- Achieve Life Sciences Inc.
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $526.6M
- $3.63B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 10
- 11
- Recent ratings
- 8
- 11
ACHV
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV
- SEC Form DEF 14A filed by Achieve Life Sciences Inc.
- SEC Form 4 filed by Director Waldman Reid Alexander
- SEC Form 4 filed by Director Farrow Jeffrey S
- New insider Waldman Reid Alexander claimed no ownership of stock in the company (SEC Form 3)
- New insider Farrow Jeffrey S claimed no ownership of stock in the company (SEC Form 3)
- Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update
- Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
- SEC Form PRE 14A filed by Achieve Life Sciences Inc.
- SEC Form EFFECT filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)